Esmée P. Hoefsmit - Concepedia

Author

Esmée P. Hoefsmit

Also Known As

E. Hoefsmit, E. P. Hoefsmit, E.P. Hoefsmit, Esmee Hoefsmit, Esmee P Hoefsmit, Esmee P. Hoefsmit, Esmée Hoefsmit, Esmée P Hoefsmit, Esmée P. Hoefsmit

Publications

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Melanoma Institute Australia Oncode Institute The University of Sydney Leiden University Medical Center

About

Esmée P. Hoefsmit is an author at The Netherlands Cancer Institute specializing in medicine, radiation oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	387
2	Immunology	4	4	367
3	Pathology	2	2	40
4	Cell Biology	1	1	15
5	Pharmacology	1	1	20

Esmée P. Hoefsmit

Publications

796

Citations

H-Index

Page 1

	Year	Citations
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers, Nature Medicine Biomarker AnalysesMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	322
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy Sonia Iyer, Shuang Zhang, Simge Yucel, Cancer Discovery	2020	130
Eosinophils capture viruses, a capacity that is defective in asthma Yanaika S. Sabogal Piñeros, Suzanne M. Bal, Annemiek Dijkhuis, Allergy	2019	106
Comprehensive analysis of cutaneous and uveal melanoma liver metastases Esmée P. Hoefsmit, Elisa A. Rozeman, Trieu My Van, Journal for ImmunoTherapy of Cancer	2020	70
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells Zhengkui Zhang, Xiangjun Kong, Maarten A. Ligtenberg, Cell Reports Medicine	2022	41
Acidity‐mediated induction of FoxP3 <sup>+</sup> regulatory T cells Disha Rao, Johanna A. Stunnenberg, Ruben Lacroix, European Journal of Immunology	2023	22
18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma Elisa A. Rozeman, Alexander M. Menzies, Oscar Krijgsman, Annals of Oncology MedicineMelanomaPathology18-Months Relapse-free SurvivalImmune Checkpoint Inhibitor	2019	20
Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma. Elisa A. Rozeman, Irene L. M. Reijers, Esmée P. Hoefsmit, Journal of Clinical Oncology Surgical OncologyImmunologyImmunoeditingPathologyArm B	2020	20
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells Esmée P. Hoefsmit, Paula T. van Royen, Disha Rao, Cancer Immunology Research T-regulatory CellApoptosisImmunologyImmunoeditingCell Death	2023	15
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation Elisa A. Rozeman, Judith M. Versluis, Karolina Sikorska, Journal for ImmunoTherapy of Cancer	2023	15

Page 1